## Note
nid: 1499998719327
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#AMBOSS::HematOnco, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::04_Pathology::28_Leukemia::Acute_Leukemia::Acute_Lymphoblastic_Leukemia::B-ALL, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::05_Pharm::30_Tisagenlecleucel, #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#SketchyPharm::Immunology-&-Biochemistry-Pharmacology::Immuno-stimulants-&-Biochemistry-Pharmacology::Enzyme-Replacement-Therapy,Gene-Therapy,and-Cystic-Fibrosis-Therapy, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::2-RelativelyHighYield
markdown: false

### Text
<div>
  <div>
    <b>Tisagenlecleucel</b> is a <b>CAR T-cell Therapy</b> that is
    indicated for relapsed {{c1::<b>B-cell acute lymphoblastic
    leukemia (B-ALL)</b>}} by targeting the {{c2::<b>CD19</b>}}
    antigen
  </div>
</div>

### Extra
<div>
  <i>- The way this drug works is that a patients T cells are
  extracted, genetically engineered to target CD19, then infused
  back into the patient</i>
</div><i>- Tisagenlecleucel has a <b>82% response rate</b></i>
<div><img src="CAR-T-chimeric-antigen-receptor.jpg"></div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy


### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_7.png"></a>
</div>

### Additional Resources


### One by one

